Zhejiang Puli Pharmaceutical

Zhejiang Puli Pharmaceutical is a prominent Chinese pharmaceutical manufacturer and a wholly-owned subsidiary of Hainan Poly Pharmaceutical. The company focuses on the development, production, and global registration of high-quality generic drugs, active pharmaceutical ingredients (APIs), and innovative diagnostic agents. Its state-of-the-art manufacturing facilities feature multiple specialized workshops for solid oral dosages, small-volume injections, eye drops, oral liquids, and prefilled syringes, all built to comply with US FDA, European Union, and Chinese GMP standards. In addition to its commercial generic portfolio, the company operates as a contract development and manufacturing organization (CDMO/CMO) for international clients. Zhejiang Puli Pharmaceutical is also advancing an innovative pipeline, highlighted by PL002, a fluorescent and magnetic resonance dual-modality contrast agent designed for the preoperative diagnosis and intraoperative navigation of primary liver cancer.